Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Open-label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention

NCT05207865 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05207865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05207865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Open-label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
March 15, 2022
Completion date
July 2, 2024
Enrollment
441 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

episodic migraine, migraine, phonophobia, photophobia